- Baxter International Inc BAX posted Q2 revenue of $3.75 billion, missing the consensus of $3.88 billion, up 21% on a reported basis, 26% on a constant currency basis, and 3% on an operational basis.
- Adjusted EPS of $0.87 increased 9%, in line with the consensus and the management guidance.
- Baxter's newly acquired Hillrom businesses – Patient Support Systems, Front Line Care, and Surgical Solutions – contributed approximately $715 million on a reported basis.
- The gross margin decreased from 39.8% to 38.8%, and the operating margin declined from 13.7% to 9.1%.
- Growth in the quarter was partially offset by a decline in Acute Therapies and BioPharma Solutions, reflecting a challenging year-over-year comparison resulting from the prior year COVID-19 related sales in those businesses.
- Outlook: Baxter expects FY22 sales growth in the high teen percentage versus the previous range of approximately 23% - 24% on a reported basis and around 2-3% on an operational basis (earlier 3%).
- It expects an adjusted EPS of $3.60 - $3.70, down from $4.12 - $4.20 anticipated previously, versus the consensus of $4.13.
- For Q3, Baxter expects an adjusted EPS of $0.79- $0.83 compared to the Wall Street estimate of $1.10.
- The company forecasts sales growth in the low single digit on an operational basis.
- Price Action: BAX shares are down 9.27% at $60.61 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
